RegulationPriority Review (United States), Accelerated Approval (United States), Priority Review (China), Breakthrough Therapy (China), Commissioner's National Priority Voucher (United States), Conditional marketing approval (Canada)

Structure/Sequence

Sequence Code 50953

Source: *****

611

Clinical Trials associated with Semaglutide (Novo Nordisk)

NCT07430332

/ Not yet recruitingPhase 2IIT

Leveraging Semaglutide for Preservation of Beta Cell Function and Restoration of Alpha Cell Function

This study seeks to evaluate the hormone responses of insulin, c-peptide, glucagon, and incretins to semaglutide, a GLP-1 receptor agonist therapy, in individuals with stage 1 type 1 diabetes. The goal of this study is to see if semaglutide can protect beta cell function in this group of people and delay the progression to stage 2 type 1 diabetes.

Start Date01 Sep 2027

Sponsor / Collaborator

Children's Hospital & Medical Center

NCT06977438

/ Not yet recruitingPhase 4IIT

Promoting Healthy Children and Youth

The rapid emergence of new and highly effective obesity medications has turned the field of pediatric weight management on its head. Adolescents living with obesity, their caregivers, healthcare providers, healthcare systems, policymakers, and payors are now wondering what role health behavior and lifestyle treatment (HBLT) has in terms of body mass index (BMI) reduction, improvements in quality of life and cardiometabolic health, and mitigating nutritional concerns when medications are used. Is intensive (26+ hours) of HBLT needed or could low intensity HBLT be an equally effective alternative; and if so, for whom? Our proposed project will answer these important questions that arise daily in the clinical setting and will generate critical new insights to guide decision-making for teens with obesity and the stakeholders who care deeply about them.

Start Date01 Jan 2027

Sponsor / Collaborator

University of Minnesota

[+2]

NCT07389941

/ Not yet recruitingPhase 4

Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation (SPICE-AF)

To evaluate whether pre-treatment with semaglutide is superior to standard care in improving freedom from atrial fibrillation (AF) at 12 months following catheter ablation in patients with obesity and symptomatic AF undergoing first-time ablation.

Start Date01 Oct 2026

Sponsor / Collaborator

Universität zu Lübeck

100 Clinical Results associated with Semaglutide (Novo Nordisk)

100 Translational Medicine associated with Semaglutide (Novo Nordisk)

100 Patents (Medical) associated with Semaglutide (Novo Nordisk)

352

Literatures (Medical) associated with Semaglutide (Novo Nordisk)

01 Mar 2026·Medicine Health Care and Philosophy

The ethics of Wegovy: promoting autonomy in pediatric care

Review

Author: Ryan, Nanette ; Savulescu, Julian

Abstract:

Semaglutide, marketed as Wegovy, Ozempic, and Rybelsus, is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that has attracted significant global attention for its appetite-suppressing and weight-loss effects. Approved for pediatric use in children aged 12 and older, Wegovy has been described as a “miracle drug” and hailed as a potential solution to the so-called “obesity epidemic.” However, prescribing medication to children raises complex ethical questions, including how best to respect young patients’ autonomy and promote their well-being. This paper focuses on one such concern: the “argument from virtue.” According to this view, Wegovy represents a morally problematic approach to weight loss because it circumvents the development of character traits—such as self-control and resilience—that are seen as integral to autonomy. We critically examine this argument, rejecting the claim that there is a single morally “right way” to lose weight, and argue that Wegovy, when prescribed within a supportive framework, may help children build and exercise autonomy. We review the drug’s function and efficacy, analyze how it might promote or hinder autonomy, and offer recommendations to support ethical prescribing practices that align with respect for children’s agency.

01 Mar 2026·JOURNAL OF MEDICAL ETHICS

Reply: The ethics of Ozempic and Wegovy

Article

Author: Ryan, Nanette

Räsänen and Ahola-Launonen recently offered a commentary on an ethical analysis I co-authored with Julian Savulescu on the use of semaglutide-based weight-loss drugs such as Ozempic. In this response, I continue the discussion by engaging their concerns about the narrow framing of our analysis with respect to the structural determinants of health and the conditions of autonomy, as well as the role of race, class and gender in shaping stigma and access to treatment. I argue that Räsänen and Ahola-Launonen’s critique and the conclusion they draw are largely in alignment with our paper and that the absence in our account of a more expansive conception of autonomy and a broader discussion of race, class and gender are fair criticisms. In what follows, I add nuance to these dimensions and caution against critiques of unjust structures that risk reproducing injustice by inadvertently denying the agency, self-respect and inclusion of marginalised groups.

01 Mar 2026·JOURNAL OF MEDICAL ETHICS

Weighty matters: Ozempic, autonomy and the ethics of health reform

Article

Author: Räsänen, Joona ; Ahola-Launonen, Johanna

Ryan and Savulescu recently offered an ethical analysis of the use of semaglutide-based weight-loss drugs such as Ozempic. In this response, we continue the discussion and argue that their framework insufficiently addresses structural inequalities and the broader political context of obesity treatment. Positioning pharmaceutical drugs as a solution to socially produced health problems narrows moral decision-making, causing structural approaches to appear less urgent and less important. We criticise the individualistic conception of autonomy commonly invoked to justify pharmaceutical choice, arguing that a proper definition of autonomy requires attention to social contexts—stigma, discrimination and economic inequality—that shape treatment decisions. We call for a broader ethical framework—one that interrogates structural injustices and reimagines health interventions beyond individual treatment—asking: is the problem our bodies or unregulated markets and environments that produce ill health in them?

2,954

News (Medical) associated with Semaglutide (Novo Nordisk)

07 May 2026

·www.prnewswire.com

Wegovy® access expanded for Medicare beneficiaries living with obesity through the Medicare GLP-1 Bridge starting July 1, 2026

Eligible Medicare patients living with obesity will have access to Wegovy ® (semaglutide) injection and pill for a $50 monthly copay Wegovy ® offers adults living with obesity significant weight loss, along with diet and exercise, and is FDA-approved to lower the risk of major CV events such as death, heart attack, or stroke in adults living with obesity with known heart disease, a claim only Wegovy ® can make Novo Nordisk's participation in the Medicare GLP-1 Bridge expands patient access to authentic, FDA-approved Wegovy ® PLAINSBORO, N.J., May 7, 2026 /PRNewswire/ -- The Medicare GLP-1 Bridge will provide eligible Medicare beneficiaries living with obesity access to Wegovy® (semaglutide) injection and tablets for a $50 monthly copay †, beginning July 1, 2026, per yesterday's announcement from the Centers for Medicare & Medicaid Services (CMS). The program represents a meaningful milestone in making FDA-approved Wegovy® accessible for millions of America's Medicare patients living with obesity, who can now work with their healthcare professional to start and stay on proven, FDA-approved treatment. Continue Reading Wegovy® pill (1.5 mg, 4mg, 9mg, 25mg) Wegovy® injection (0.25mg, 0.5mg, 1.0mg, 1.7mg, 2.4mg, 7.2mg) "Obesity is a serious, common chronic disease facing older Americans, and Wegovy® is the only weight management medicine proven to reduce the risk of heart attack, stroke, or cardiovascular death in patients who also have known heart disease. That distinction matters for seniors age 65 and older, who have a high burden of both conditions," said Jamey Millar, executive vice president, US Operations of Novo Nordisk. "We welcome the Medicare GLP-1 Bridge as an important step in getting Wegovy® to more patients and will continue to work with CMS, healthcare professionals, pharmacists, and patient advocates to support implementation and help eligible seniors access the care they need and deserve." The Medicare GLP-1 Bridge provides eligible patients access to Wegovy® for weight management. The Medicare GLP-1 Bridge will be available nationwide across all states and territories, providing eligible patients access to all doses and formulations of Wegovy® injection and Wegovy® pill, and will run through the end of 2027. It is important to note that Wegovy® will be available for eligible Medicare beneficiaries for the other FDA-approved indications through their normal Part D benefits, including to reduce the risk of major adverse cardiovascular events in adults with established CV disease with either obesity or overweight. Novo Nordisk is actively working with CMS, healthcare professionals, pharmacists, and patient advocacy organizations to streamline implementation, raise awareness among eligible beneficiaries, and help ensure patients can access the medicines they need. Additional program details are available at CMS.gov. Expanding affordable access to medicines is a priority for Novo Nordisk, and the Medicare GLP-1 Bridge builds on a sustained effort to ensure patients can access authentic, FDA-approved Wegovy®. Patients seeking information on affordability options, with or without insurance, are encouraged to visit NovoCare.com. †Terms apply. For eligible Medicare patients prescribed Wegovy® for a covered FDA-approved indication. Eligibility criteria will be determined by CMS. This information is not a guarantee of coverage. Month defined as 1 box of 4 pens of Wegovy® and 1 bottle of 30 tablets of Wegovy®. About obesity Obesity is a serious, chronic, progressive, and complex disease that requires long-term management.1-3 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people living with obesity from losing weight and keeping it off.1,3 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.4,5 About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs approximately 10,000 people throughout the country across more than 10 manufacturing, R&D and corporate locations in seven states plus Washington DC. For more information, visit novonordisk-us.com, Facebook, Instagram, and X. What is Wegovy®? Wegovy® (semaglutide) injection is a prescription medicine used with a reduced-calorie diet and increased physical activity to: reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight. help adults and children aged 12 years and older with obesity, or some adults with excess weight (overweight) who also have weight-related medical problems to lose weight and keep the weight off. Wegovy® (semaglutide) tablets are a prescription medicine used with a reduced-calorie diet and increased physical activity to: reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight. help adults with obesity, or some adults with excess weight (overweight) who also have weight related medical problems to lose weight and keep the weight off. Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines. It is not known if Wegovy® injection is safe and effective: to reduce the risk of major cardiovascular events (death, heart attack, or stroke) in people under 18 years to help children under 12 years of age lose weight and keep the weight off. It is not known if Wegovy® tablets are safe and effective for use in people under 18 years of age. Important Safety Information What is the most important information I should know about Wegovy®? Wegovy ® may cause serious side effects, including: Possible thyroid tumors, including cancer. Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, Wegovy® and other medicines that work like Wegovy® caused thyroid tumors, including thyroid cancer. It is not known if Wegovy® will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people Do not use Wegovy® if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Do not use Wegovy® if: you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) you have had a serious allergic reaction to semaglutide or any of the ingredients in Wegovy® injection or Wegovy® tablets. See symptoms of serious allergic reaction in "What are the possible side effects of Wegovy®?" Before using Wegovy®, tell your healthcare provider if you have any other medical conditions, including if you: have or have had problems with your pancreas or kidneys have type 2 diabetes and a history of diabetic retinopathy are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation) are pregnant or plan to become pregnant. Wegovy® may harm your unborn baby. You should stop using Wegovy® 2 months before you plan to become pregnant are breastfeeding or plan to breastfeed. Breastfeeding is not recommended during treatment with Wegovy® tablets. It is not known if Wegovy® when received through an injection passes into your breast milk Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy® may affect the way some medicines work and some medicines may affect the way Wegovy® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy® slows stomach emptying and can affect medicines that need to pass through the stomach quickly. What are the possible side effects of Wegovy®? Wegovy® may cause serious side effects, including: inflammation of your pancreas (pancreatitis). Stop using Wegovy® and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back gallbladder problems. Wegovy® may cause gallbladder problems, including gallstones. Some gallstones may need surgery. Call your healthcare provider if you have symptoms, such as pain in your upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay-colored stools increased risk of low blood sugar (hypoglycemia), especially those who also take medicines for diabetes such as insulin or sulfonylureas. This can be a serious side effect. Talk to your healthcare provider about how to recognize and treat low blood sugar and check your blood sugar before you start and while you take Wegovy®. Signs and symptoms of low blood sugar may include dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Wegovy®. Tell your healthcare provider if you have stomach problems that are severe or will not go away serious allergic reactions. Stop using Wegovy® and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat change in vision in people with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Wegovy® increased heart rate. Wegovy® can increase your heart rate while you are at rest. Tell your healthcare provider if you feel your heart racing or pounding in your chest and it lasts for several minutes food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Wegovy® may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Wegovy® before you are scheduled to have surgery or other procedures The most common side effects of Wegovy® may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, changes in skin sensations, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and hair loss. Please click here for Prescribing Information including Boxed Warning and Medication Guide for Wegovy ® . Contacts for further information References: Kaplan LM, Golden A, Jinnett K, et al. Perceptions of barriers to effective obesity care: results from the national action study. Obesity. 2018;26(1):61–69. Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715–723. Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22 (Suppl 3):1–203. Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide 25 mg in adults with overweight or obesity. N Engl J Med. 2025; 393:1077-1087. DOI: 10.1056/NEJMoa2500969. Centers for Disease Control and Prevention. Risk Factors for Obesity. Last accessed: December 2025. Available at: SOURCE Novo Nordisk 21% more press release views with Request a Demo

Drug Approval

06 May 2026

·www.fiercepharma.com

Novo Nordisk, Eli Lilly fined by French regulator over obesity drug promotions

France’s drug regulator fined Novo Nordisk and Eli Lilly over obesity awareness campaigns it said crossed into indirect promotion. As the promotion battle between old rivals Novo Nordisk and Eli Lilly heats up, regulators in France are reminding the world’s two biggest obesity drugmakers what happens when promotion goes too far.Pharma companies are not allowed to market prescription drugs directly to patients in Europe, but they can run awareness campaigns around the diseases they treat.In these cases, however, both companies appear to have crossed the line, as regulators determined their campaigns amounted to indirect promotion of prescription treatments in violation of the country’s rules.First up is Novo. The French drug regulator, Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), took issue with several of Novo’s obesity campaigns across the country and online last year.This included a campaign in Paris in 2025 just before the summer featuring the line, “I’ve decided to act for myself & for my health,” which the ANSM said was “highlighted with, in the background, an image depicting overweight people, smiling again at the idea of ‘taking action.’”In October, the company also posted on social media the slogan, “More effort, less result? Menopause changes the game. Your gynaecologist can support you,” alongside an image of a woman entering menopause.There was also a video with the tagline, “Changing your perspective is already progress” and “Obesity? Overweight? Visit audeladupoids.fr,” which the regulator said circulated on social media, “featuring a woman in her forties who was overweight, explaining to the general public how she decided to take action, notably by discussing the issue with her doctor.” The regulator said these messages came “within a broader context of misuse of the GLP-1 analog class, which has received significant media attention and been the subject of numerous communications from health authorities.”The ANSM took issue with the fact that the messaging focused on medication as a response to obesity without sufficiently emphasizing other approaches, such as diet and exercise. Given the high public awareness of GLP-1 drugs, the regulator said the campaigns were likely to be understood as promoting prescription treatments, even without naming specific products.In France, Wegovy is prescribed as a second-line treatment for obesity, not for people with a lower body mass index (BMI) or those who simply “have kilos to lose,” as the regulator put it. Because the campaigns did not clearly define who these medicines are intended for, Novo was fined €783,838.20 ($919,688) for violating the Public Health Code.Novo was also hit for similar promotions tied to its other injectable obesity drug, Saxenda, receiving a separate €1 million ($1.17 million) fine for those breaches.Lilly was also fined for breaching the country’s drug promotion rules. Last year, just before the summer, it publicized a disease awareness campaign through posters in six major French cities—“notably in the metro, in the press, and on social media,” according to the French regulator—which Lilly has described as titled “Obesity is a sick person’s problem,” according to comments reported by Le Monde.The regulator said that, as with Novo, the widespread recognition of these obesity treatments meant the campaign was likely to encourage members of the public—regardless of their weight or BMI—to seek out prescription options.“This communication campaign, by focusing solely on medications indicated for the treatment of obesity without naming them, therefore tends to encourage the general public, regardless of their weight and body mass index (BMI), to use the products in the Mounjaro range.”The ANSM fined Lilly €108,766 ($127,591) for the breach.The enforcement action comes amid a new branding battle between Lilly and Novo in the U.S.Just last week, Novo announced a major branding shift for its semaglutide franchise, dropping the Rybelsus name in the U.S. in favor of “Ozempic pill,” while renaming its Ozempic injectable “Ozempic injection.”Earlier this year, the company also updated its obesity franchise branding to “Wegovy pill” for its oral candidate and “Wegovy injection” for the pen version.At the same time, Lilly has launched its newly approved GLP-1 drug Foundayo in the U.S., based on the ingredient orforglipron, which differs from the compound used in its obesity and diabetes drugs Mounjaro and Zepbound.

Drug Approval

06 May 2026

·www.fiercebiotech.com

Novo CEO insists ‘no change in plan’ for CagriSema launch after single-chamber device ditched

\"We believe that we will be able to have the global launches as we intend to, without the coformulation [being] needed,\" CEO Maziar Mike Doustdar told Fierce.\n Novo Nordisk’s CEO has insisted that plans to launch the GLP-1/amylin combo treatment CagriSema remain on track, despite the pharma ending hopes of delivering the therapy in a single-chamber device.The Danish drugmaker submitted CagriSema—which combines Wegovy’s ingredient semaglutide with the experimental amylin receptor agonist cagrilintide—to the FDA last December. The fixed-dose injectable treatment is set to be delivered in a dual-chamber system.Novo had also been working on a co-formulation version that could have potentially allowed for CagriSema to be administered in a single-chamber device. However, the company revealed in its first-quarter earnings documents (PDF) Wednesday that it has terminated this co-formulation project “due to portfolio considerations.”Novo CEO Maziar Mike Doustdar explained to Fierce this morning that this decision doesn’t impact the broader strategy for CagriSema.“We are incredibly excited about the upcoming launch of CagriSema, and we believe that we will be able to have the global launches as we intend to, without the co-formulation [being] needed,” he told Fierce Biotech on a May 6 call with journalists. “So there is no change in plan.”Novo is anticipating U.S. approval of CagriSema in the fourth quarter of the year followed by a launch early in 2027. Doustdar also highlighted to Fierce that the company has made progress with zenagamtide—the new name for the dual GLP-1 and amylin agonist amycretin. The company has now launched various phase 3 studies of zenagamtide for obesity and related conditions like sleep apnea and knee osteoarthritis.The pharma expects to launch zenagamtide “soon after” CagriSema, Doustdar said.“So with the combination of CagriSema in a dual chamber pen that we have discussed before, as well as, of course, the unimolecule zenagamtide … we feel like we are very well covered for the upcoming few years’ launches,” the CEO told Fierce on the call.Novo may be keeping the faith in CagriSema, but investors’ hopes have been dimmed after some disappointing phase 3 readouts in recent months. Not only did the therapy fail to deliver the 25% weight loss observers had been waiting for, but CagriSema was also unable to beat Eli Lilly’s obesity blockbuster Zepbound in a head-to-head study.Doustdar is still hoping that CagriSema can find its own niche in an obesity space that is set to rapidly fill up with rival products.“Amylin biology is something very interesting,” the CEO said on the call. “We see most of our competitors also getting excited about that, but we are very happy that despite [the] very crowded space, we’re going to be—once again—first to launch an amylin in combinations with a GLP-1,” he said.

Phase 3

100 Deals associated with Semaglutide (Novo Nordisk)

External Link

KEGG	Wiki	ATC	Drug Bank
D10025	Semaglutide (Novo Nordisk)	A10BJ06	DB13928

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Heart Diseases	United Kingdom	Novo Nordisk A/S	01 Apr 2026
Fibrosis, Liver	United States	Novo Nordisk, Inc.	22 Dec 2025
Pulmonary Fibrosis	Canada	Novo Nordisk Canada, Inc.	21 Dec 2025
Cardiovascular Diseases	United States	Novo Nordisk, Inc.	15 Aug 2025
Metabolic Dysfunction Associated Steatohepatitis	United States	Novo Nordisk, Inc.	15 Aug 2025
Metabolic Dysfunction Associated Steatohepatitis	United States	Novo Nordisk A/S	15 Aug 2025
Chronic Kidney Diseases	United States	Novo Nordisk, Inc.	28 Jan 2025
Chronic Kidney Diseases	United States	Novo Nordisk A/S	28 Jan 2025
Stroke	Australia	Novo Nordisk Pharmaceuticals Pty Ltd.	16 Dec 2024
Myocardial Infarction	Canada	Novo Nordisk Canada, Inc.	27 Nov 2024
Obesity	United States	Novo Nordisk, Inc.	04 Jun 2021
Overweight	United States	Novo Nordisk, Inc.	04 Jun 2021
Diabetes Mellitus, Type 2	United States	Novo Nordisk, Inc.	05 Dec 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Albuminuria	Phase 3	Canada	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Germany	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Netherlands	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Spain	Novo Nordisk A/S	14 Mar 2022
Osteoarthritis, Knee	Phase 3	United States	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Canada	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Colombia	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Denmark	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	France	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Norway	Novo Nordisk A/S	01 Oct 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05649137 (STEP UP T2D, CTgov)	Phase 3	Diabetes Mellitus, Type 2 \| Obesity	512	Semaglutide (Semaglutide 7.2 mg)	qruganfdms(cihschxkyo) = masaytnbcy rqzheradxa (jgbsxtizjb, 8.7) View more	-	27 Apr 2026
				Semaglutide (Semaglutide 2.4 mg)	qruganfdms(cihschxkyo) = hlrgetqoqo rqzheradxa (jgbsxtizjb, 8.1) View more
NCT05646706 (STEP UP, CTgov)	Phase 3	Obesity	1,407	Semaglutide (Semaglutide 7.2 mg)	zccibssyaz(kfcwieamrh) = ukhcuudyso ncnsswvflg (cnnnrheixt, 10.6) View more	-	23 Apr 2026
				Placebo (Placebo)	zccibssyaz(kfcwieamrh) = vpsibpktvo ncnsswvflg (cnnnrheixt, 7.1) View more
NCT05144984 (CTgov)	Phase 2	Diabetes Mellitus, Type 2	500	Placebo (NNC080-0389)+Semaglutide	kfagtqhfra(ojuewwmsie) = uyzxlatdpq pceyiurzir (htknvmigvv, 0.9) View more	-	09 Apr 2026
NCT03914326 (SOUL, Pubmed \| JAMA Cardiol)	Phase 3	Diabetes Mellitus, Type 2	9,650	Oral Semaglutide	fomxybxred(yeyrfkgnbp) = mgwhexgzvu rxzcdobtsq (plffzltmmu, 1.01 - 1.02) View more	Positive	25 Mar 2026
NCT05564117 (OASIS 4, CTgov)	Phase 3	Obesity	307	Semaglutide	okahzdbigo(lwubguofvi) = buhurumbvx pjjgpckqhy (swkytmtmfx, 10.5) View more	-	25 Feb 2026
NCT05891496 (CTgov)	Phase 3	Alzheimer Disease	23	Semaglutide (Semaglutide)	ubzencpibk(ibarvjyehb) = njeqzgzycy lazrjqvnet (zmlryprogg, 29.68) View more	-	24 Feb 2026
				placebo+semaglutide (Placebo)	ubzencpibk(ibarvjyehb) = azcxcrkvds lazrjqvnet (zmlryprogg, 25.70) View more
NCT03819153 (FLOW, Pubmed \| Nephrol Dial Transplant)	Phase 3	COVID-19 \| Infectious Diseases	7,040	Semaglutide 1.0 mg	ovwljvehkj(ofzrwgsdto) = meluxkloqj diwyfohcdg (pnbmtzzlac ) View more	Positive	23 Feb 2026
				Placebo	ovwljvehkj(ofzrwgsdto) = jicbadaicu diwyfohcdg (pnbmtzzlac ) View more
NCT03819153 (FLOW, Pubmed \| Clin J Am Soc Nephrol)	Phase 3	Chronic Kidney Diseases	3,533	Semaglutide 1 mg	qpfyovdtbc(pdjovdpqan) = wxyejyylgv dkeshlvvhl (tqwxgaxqvz ) View more	Positive	18 Feb 2026
				Placebo	qpfyovdtbc(pdjovdpqan) = sljtigbnex dkeshlvvhl (tqwxgaxqvz ) View more
NCT04019197 (CTgov)	Phase 2	HIV-Associated Lipodystrophy Syndrome \| Acquired Immunodeficiency Syndrome \| Lipohypertrophy ... View more	108	Semaglutide Injectable Product (Participants With HIV and Lipohypertrophy: Semaglutide Arm)	kcicklnoib(mqeexgrsxw) = oznyhblrdr ynlgjglrqv (chxuewbwrn, lkqifzvkxz - nicuncxiup) View more	-	17 Feb 2026
				Placebo (Participants With HIV and Lipohypertrophy: Placebo Arm)	kcicklnoib(mqeexgrsxw) = riiuqrrokf ynlgjglrqv (chxuewbwrn, pypcjdkwmj - mpfnhqysfj) View more
NCT04779697 (CTgov)	Phase 1	Obesity	96	GLP-1 analogue - semaglutide (GLP-1a)	vqsaurvhht(kxpdkrneqq) = zruupmffwj jbuwuqrkkk (kwaturlmmm, 0.6) View more	-	10 Feb 2026
				Placebo (Placebo)	vqsaurvhht(kxpdkrneqq) = fhobumxmlb jbuwuqrkkk (kwaturlmmm, 0.4) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis